Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Gains from Investment Securities (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Gains from Investment Securities data on record, last reported at $225000.0 in Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to $225000.0; the TTM value through Sep 2025 reached $225000.0, up 13.64%, while the annual FY2024 figure was $2.0 million, 1514.39% up from the prior year.
  • Gains from Investment Securities reached $225000.0 in Q3 2025 per ASMB's latest filing, roughly flat from $225000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.0 million in Q4 2024 and bottomed at -$1.7 million in Q2 2021.
  • Average Gains from Investment Securities over 5 years is $151660.6, with a median of $120000.0 recorded in 2021.
  • The widest YoY moves for Gains from Investment Securities: up 1100.0% in 2023, down 2712.01% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $1.8 million in 2021, then plummeted by 85.09% to $261000.0 in 2022, then fell by 24.14% to $198000.0 in 2023, then surged by 892.93% to $2.0 million in 2024, then crashed by 88.56% to $225000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $225000.0 in Q3 2025, $225000.0 in Q2 2025, and $2.0 million in Q4 2024.